Barrett's esophagus: a review of the literature
- PMID: 21461873
- DOI: 10.1007/s11605-011-1485-y
Barrett's esophagus: a review of the literature
Abstract
Barrett's esophagus (BE) is the premalignant lesion of esophageal adenocarcinoma (EAC) defined as specialized intestinal metaplasia of the tubular esophagus that results from chronic gastroesophageal reflux. Which patients are at risk of having BE and which are at further risk of developing EAC has yet to be fully established. Many aspects of the management of BE have changed considerably in the past 5 years alone. The aim of this review is to define the critical elements necessary to effectively manage individuals with BE. The general prevalence of BE is estimated at 1.6-3% and follows a demographic distribution similar to EAC. Both short-segment (<3 cm) and long-segment (≥3 cm) BE confer a significant risk for EAC that is increased by the development of dysplasia. The treatment for flat high-grade dysplasia is endoscopic radiofrequency ablation therapy. The benefits of ablation for non-dysplastic BE and BE with low-grade dysplasia have yet to be validated. By understanding the intricacies of the development, screening, surveillance, and treatment of BE, new insights will be gained into the prevention and early detection of EAC that may ultimately lead to a reduction in morbidity and mortality in this patient population.
Similar articles
-
The diagnosis and management of Barrett's esophagus.Adv Surg. 1999;33:29-68. Adv Surg. 1999. PMID: 10572561 Review.
-
Endoscopic therapy of esophageal premalignancy and early malignancy.J Natl Compr Canc Netw. 2011 Aug 1;9(8):890-9. doi: 10.6004/jnccn.2011.0073. J Natl Compr Canc Netw. 2011. PMID: 21900219
-
Screening and surveillance for complications related to gastroesophageal reflux disease.Am J Med. 2001 Dec 3;111 Suppl 8A:130S-136S. doi: 10.1016/s0002-9343(01)00851-8. Am J Med. 2001. PMID: 11749938 Review.
-
Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.Gastrointest Endosc Clin N Am. 2021 Jan;31(1):27-41. doi: 10.1016/j.giec.2020.08.002. Epub 2020 Oct 21. Gastrointest Endosc Clin N Am. 2021. PMID: 33213798 Free PMC article. Review.
-
Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett's esophagus.Surg Endosc. 2011 Mar;25(3):830-4. doi: 10.1007/s00464-010-1270-0. Epub 2010 Jul 30. Surg Endosc. 2011. PMID: 20676687
Cited by
-
Glutathione Peroxidase 7 Suppresses Bile Salt-Induced Expression of Pro-Inflammatory Cytokines in Barrett's Carcinogenesis.J Cancer. 2014 Jun 10;5(7):510-7. doi: 10.7150/jca.9215. eCollection 2014. J Cancer. 2014. PMID: 24963355 Free PMC article.
-
Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus.Oncogene. 2014 Jan 16;33(3):347-57. doi: 10.1038/onc.2012.586. Epub 2013 Jan 14. Oncogene. 2014. PMID: 23318448 Free PMC article.
-
Oesophageal Adenocarcinomas: Where Do We Stand Today?Cancers (Basel). 2020 Dec 31;13(1):109. doi: 10.3390/cancers13010109. Cancers (Basel). 2020. PMID: 33396388 Free PMC article.
-
Glutathione peroxidase 7 has potential tumour suppressor functions that are silenced by location-specific methylation in oesophageal adenocarcinoma.Gut. 2014 Apr;63(4):540-51. doi: 10.1136/gutjnl-2013-304612. Epub 2013 Apr 12. Gut. 2014. PMID: 23580780 Free PMC article.
-
Dietary sugar/starches intake and Barrett's esophagus: a pooled analysis.Eur J Epidemiol. 2017 Nov;32(11):1007-1017. doi: 10.1007/s10654-017-0301-8. Epub 2017 Sep 1. Eur J Epidemiol. 2017. PMID: 28864851 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous